openPR Logo
Press release

Lymphocyte Activation Gene - 3 Protein Market : North America is expected to witness significant growth By 2026 With Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc

02-27-2019 06:45 AM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Lymphocyte Activation Gene - 3 Protein

Lymphocyte Activation Gene - 3 Protein

Immune checkpoint receptors such as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene - 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene - 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene - 3 protein is associated with T cell exhaustion in which the T cells become desensitized and lose their ability to function.

LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene - 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.

Ask For Sample Copy of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/2027

Lymphocyte Activation Gene - 3 Protein Market Drivers

Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene - 3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.

Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date - August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period.

Manufacturers and researchers are focused on development of novel therapies that aid in treatment of cancer. High prevalence of cancer is expected to boost growth of the market. According to National Cancer Institute, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S., in 2018. The most common types of cancer are lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others. According to Cancer Research UK, 2015, around 54,900 new cases of breast cancer are registered in the UK, which account for 15% of all new cancer cases, annually.

Lymphocyte Activation Gene - 3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene - 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.

Lymphocyte Activation Gene - 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

Talk To Our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2027

High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene - 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lymphocyte Activation Gene - 3 Protein Market : North America is expected to witness significant growth By 2026 With Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc here

News-ID: 1619373 • Views: 533

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Lymphocyte

Tumor Infiltrating Lymphocyte (TIL) Market 2021 | Detailed Report
The Tumor Infiltrating Lymphocyte (TIL) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Tumor Infiltrating Lymphocyte (TIL) research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force. Download FREE
Global Biosimilar Lymphocyte Modulator Market 2021 | Size, Growth, Demand, Oppor …
Get up to 33% off on ALL market research reports at The Business Research Company's holiday sale; buy now! https://www.thebusinessresearchcompany.com/global-market-reports ‘Biosimilar Lymphocyte Modulator Global Market Report 2021 - COVID-19 Growth And Change’ by The Business Research Company is the most comprehensive report available on this market, with analysis of the market’s historic and forecast growth, drivers and restraints causing this, and highlights of the opportunities that companies in the industry can take
Global Tumor Infiltrating Lymphocyte (TIL) Market Huge Growth Opportunity betwee …
LP INFORMATION recently released a research report on the Tumor Infiltrating Lymphocyte (TIL) market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Tumor Infiltrating Lymphocyte (TIL) market by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Tumor Infiltrating Lymphocyte (TIL) market,
Lymphocyte Activation Gene - 3 Protein Market - Size, Share, Outlook, and Opport …
Immune checkpoint receptors such as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene - 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene - 3 turns off
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or …
Market Research Hub has added a new report tilted "Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018" to its vast database of market reports. Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or …
ReportsWorldwide has announced the addition of a new report title Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 38 molecules. Out of which approximately 37 molecules are developed by companies